LIVIVO - Search results -

Search results

Result 1 - 10 of total 36

Search options

Article ; Online: Reasons against routine determination of plasma trough levels in PWH treated with intramuscular long acting cabotegravir and rilpivirine as of today.

Buzón-Martín, Luis / Troya, Jesus

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

2024

Language	English
Publishing date	2024-03-14
Publishing country	United States
Document type	Journal Article
ZDB-ID	1099781-7
ISSN	1537-6591 ; 1058-4838
ISSN (online)	1537-6591
ISSN	1058-4838
DOI	10.1093/cid/ciae141
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1505: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 480: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Weight gain in HIV-infected individuals using distinct antiretroviral drugs.

Buzón-Martín, Luis

AIDS reviews

2020 Volume 22, Issue 3, Page(s) 158–167

Abstract: Following the initiation of antiretroviral therapy, most HIV-infected individuals experience significant weight gain. It was originally thought to result from reduced energy consumption associated with suppression of overt virus replication. However, ... ...

Abstract	Following the initiation of antiretroviral therapy, most HIV-infected individuals experience significant weight gain. It was originally thought to result from reduced energy consumption associated with suppression of overt virus replication. However, recent evidence suggests that is not simply a back to normal phenomenon. Indeed, a differential influence on weight has been noticed for distinct antiretroviral drugs, some of which may produce abnormal body weight gain and metabolic disturbances. Treatment with integrase inhibitors in particular leads to significant increases in body mass index. By contrast, protease inhibitors might protect from undesirable weight gain. Ultimately, the development of overweight and obesity in an aging HIV population may increase the risk of cardiovascular events and should be prevented. In this scenario, the differential influence on weight gain using distinct antiretroviral agents might provide an opportunity for personalized medicine, adapting the most convenient drug regimen to each patient.
MeSH term(s)	Anti-HIV Agents/adverse effects ; Anti-HIV Agents/therapeutic use ; HIV Infections/drug therapy ; HIV-1 ; Humans ; Weight Gain/drug effects
Chemical Substances	Anti-HIV Agents
Language	English
Publishing date	2020-11-26
Publishing country	Spain
Document type	Journal Article ; Review
ZDB-ID	2086783-9
ISSN	1698-6997 ; 1139-6121
ISSN (online)	1698-6997
ISSN	1139-6121
DOI	10.24875/AIDSRev.M20000036
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5711: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the literature.

Buzon-Martin, Luis / Navarro-San Francisco, Carolina / Fernandez-Regueras, María / Sanchez-Gomez, Leticia

The Journal of antimicrobial chemotherapy

2024

Abstract: Objectives: The in vivo selection of E157Q plus R263K has not been reported in patients treated with coformulated bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). To the best of our knowledge, we hereby report the first case of high-grade ... ...

Abstract	Objectives: The in vivo selection of E157Q plus R263K has not been reported in patients treated with coformulated bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). To the best of our knowledge, we hereby report the first case of high-grade INSTI resistance associated with the presence of these aminoacidic substitutions in a treatment-experienced HIV patient treated with BIC/FTC/TAF. Methods: Clinical case report and review of the literature. Results: A heavily treatment-experienced patient was switched to BIC/FTC/TAF due to drug-drug interactions after being diagnosed with disseminated Mycobacterium avium-intracellulare disease. He had been treated before with raltegravir with poor adherence. No mutations in the integrase gene were detected 1 year after finishing treatment with raltegravir. Months after being switched to BIC/FTC/TAF, and again with poor adherence documented, virological failure (VF) was detected. The polymorphic substitution E157Q and the resistance mutation R263K in the integrase gene were detected, as well as M184V, among other mutations in the reverse transcriptase gene. The patient is currently being treated with dolutegravir q12h plus boosted darunavir along with directly observed treatment, and for the first time in 20 years, plasmatic viral load values are below 100 copies/mL. Conclusions: This case illustrates that the combination of E157Q and R263K plus M184V can be selected in vivo in a clinical scenario of poor adherence with BIC/FTC/TAF, although it is a very rare phenomenon. Previous VF with first-generation integrase strand transfer inhibitors (INSTIs) should be kept in mind when switching patients to second-generation INSTIs.
Language	English
Publishing date	2024-04-01
Publishing country	England
Document type	Journal Article
ZDB-ID	191709-2
ISSN	1460-2091 ; 0305-7453
ISSN (online)	1460-2091
ISSN	0305-7453
DOI	10.1093/jac/dkae085
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1197: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 124: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Clonal spread of fluconazole-resistant C. parapsilosis in patients admitted to a referral hospital located in Burgos, Spain, during the COVID-19 pandemic.

Mantecón-Vallejo, María de Los Ángeles / Mesquida, Aina / Ortiz, María de Valle / Buzón-Martín, Luis / Ossa-Echeverri, Sergio / Fisac-Cuadrado, Lourdes / Megías-Lobón, Gregoria / Ortega-Lafont, María Pilar / Muñoz, Patricia / Escribano, Pilar / Guinea, Jesús

Mycoses

2024 Volume 67, Issue 1, Page(s) e13685

Abstract: Background: Fluconazole-resistant Candida parapsilosis (FRCP) is a matter of concern in Spain.: Objectives: We here report a FRCP spread across a 777-bed referral hospital located in Burgos, Spain, during the COVID-19 pandemic.: Patients/methods: ... ...

Abstract	Background: Fluconazole-resistant Candida parapsilosis (FRCP) is a matter of concern in Spain. Objectives: We here report a FRCP spread across a 777-bed referral hospital located in Burgos, Spain, during the COVID-19 pandemic. Patients/methods: In April 2021, an FRCP isolate (MIC = 64 mg/L, E-test®) from a hospitalised patient was detected. Up to June 2022, all C. parapsilosis isolates (n = 35) from hospitalised patients (n = 32) were stored and genotyped using microsatellite markers, and their antifungal susceptibilities were studied (EUCAST); FRCP isolates were molecularly characterised. Results: We detected 26 FRCP isolates collected between 2021 (n = 8) and 2022 (n = 18); isolates were susceptible to amphotericin B, echinocandins and ibrexafungerp. FRCP isolates were grouped into three genotypes: CP-707 and CP-708 involved isolates harbouring the Y132F + R398I ERG11p substitutions (n = 24) and were clonally related; the remaining CP-675 genotype involved isolates harbouring the G458S ERG11p substitution (n = 2). FRCP genotypes were genetically related to the FRCP genotypes found in Madrid and were unrelated to fluconazole-susceptible ones. Patients harbouring FRCP were mainly (n = 22/23) admitted to intensive care units. Most patients had received broad-spectrum antibiotics (n = 22/23), and/or antifungal therapy with azoles (n = 14/23) within the 30 days prior to FRCP isolation. Thirteen patients were colonised, 10 of whom were infected and presented candidaemia (n = 8/10), endovascular infection (n = 1/10) or complicated urinary infection (n = 1/10). Overall nonattributable 30-day mortality was 17% (n = 4/23). Conclusions: We report an outbreak caused by FRCP affecting patients admitted to the ICU of a referral hospital located in Burgos. Patients harbouring FRCP had a higher fluconazole use than those carrying susceptible isolates.
MeSH term(s)	Humans ; Fluconazole/pharmacology ; Fluconazole/therapeutic use ; Antifungal Agents/pharmacology ; Antifungal Agents/therapeutic use ; Candida parapsilosis ; Spain/epidemiology ; Pandemics ; Microbial Sensitivity Tests ; Drug Resistance, Fungal/genetics ; COVID-19/epidemiology ; Hospitals ; Referral and Consultation
Chemical Substances	Fluconazole (8VZV102JFY) ; Antifungal Agents
Language	English
Publishing date	2024-01-28
Publishing country	Germany
Document type	Journal Article
ZDB-ID	392487-7
ISSN	1439-0507 ; 0933-7407
ISSN (online)	1439-0507
ISSN	0933-7407
DOI	10.1111/myc.13685
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.176: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Etoposide for Cytokine Storm Because of Coronavirus Disease 2019.

Delgado-López, Pedro David / Buzón-Martín, Luis / Montero-Baladia, Miguel / Astigarraga, Itziar

Chest

2021 Volume 159, Issue 4, Page(s) 1678–1679

MeSH term(s)	COVID-19 ; Cytokine Release Syndrome ; Cytokines ; Etoposide ; Humans ; SARS-CoV-2 ; Salvage Therapy
Chemical Substances	Cytokines ; Etoposide (6PLQ3CP4P3)
Language	English
Publishing date	2021-04-06
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	1032552-9
ISSN	1931-3543 ; 0012-3692
ISSN (online)	1931-3543
ISSN	0012-3692
DOI	10.1016/j.chest.2020.10.090
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui III Zs.45: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 349: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review.

Buzón-Martín, Luis / Zollner-Schwetz, I / Tobudic, Selma / Cercenado, Emilia / Lora-Tamayo, Jaime

Antibiotics (Basel, Switzerland)

2021 Volume 10, Issue 6

Abstract: Dalbavancin (DAL) is a lipoglycopeptide with bactericidal activity against a very wide range of Gram-positive microorganisms. It also has unique pharmacokinetic properties, namely a prolonged half-life (around 181 h), which allows a convenient weekly ... ...

Abstract	Dalbavancin (DAL) is a lipoglycopeptide with bactericidal activity against a very wide range of Gram-positive microorganisms. It also has unique pharmacokinetic properties, namely a prolonged half-life (around 181 h), which allows a convenient weekly dosing regimen, and good diffusion in bone tissue. These features have led to off-label use of dalbavancin in the setting of bone and joint infection, including prosthetic joint infections (PJI). In this narrative review, we go over the pharmacokinetic and pharmacodynamic characteristics of DAL, along with published in vitro and in vivo experimental models evaluating its activity against biofilm-embedded bacteria. We also examine published experience of osteoarticular infection with special attention to DAL and PJI.
Language	English
Publishing date	2021-05-31
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2681345-2
ISSN	2079-6382
ISSN	2079-6382
DOI	10.3390/antibiotics10060656
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The secret in his eyes.

Monasterio Bel, Jorge / Buzón Martín, Luis / Navarro San Francisco, Carolina / Gordón Bolaños, Carmen

Enfermedades infecciosas y microbiologia clinica (English ed.)

2022 Volume 40, Issue 10, Page(s) 576–577

Language	English
Publishing date	2022-11-01
Publishing country	Spain
Document type	Case Reports
ISSN	2529-993X
ISSN (online)	2529-993X
DOI	10.1016/j.eimce.2022.02.015
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48-96 weeks of RETROBIC Study.

Troya, Jesús / Pousada, Guillermo / Micán, Rafael / Galera, Carlos / Sanz, José / de Los Santos, Ignacio / Dueñas, Carlos / Cabello, Noemí / Martín, Cristina / Galindo, María Josefa / Garcinuño, María Ángeles / Pedrero-Tomé, Roberto / Buzón, Luis

The Journal of antimicrobial chemotherapy

2024 Volume 79, Issue 3, Page(s) 595–607

Abstract: Background: Switching strategy with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) has become a gold standard for people living with HIV (PLWH), achieving high efficacy and safety rates. However, data regarding immune status in long-term real- ...

Abstract	Background: Switching strategy with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) has become a gold standard for people living with HIV (PLWH), achieving high efficacy and safety rates. However, data regarding immune status in long-term real-life cohorts of pretreated patients are needed. Methods: We performed a multicentre, non-controlled, retrospective study in virologically suppressed PLWH switching to B/F/TAF. We evaluated CD4+, CD8+ and CD4+/CD8+ ratio, efficacy and safety at weeks 48 and 96. Results: The study comprised 1966 PLWH from 12 hospitals in Spain, of whom 80% were men, and the median age was 51.0 [42.0-57.0] years. The median time of HIV infection was 18.0 [10.0-27.0] years. No significant changes in CD4+, CD8+ T cells, or CD4+/CD8+ were observed after 96 weeks. Nevertheless, in women at weeks 48 and 96, we found a significant increase of CD4+ T cells and a significant decrease in CD8+ T cells. In patients ≥60 years at week 96, CD4 T cells significantly increased and CD8+ T cells significantly decreased at week 48. The on-treatment analysis revealed HIV-RNA <50 copies/mL in 95.6% (1700/1779) and 96.7% (1312/1356) of patients at weeks 48 and 96, respectively. The rates increased to 99.2% (1765/1779) and 99.7% (1352/1356) when considering HIV-RNA <200 copies/mL. No resistance mutations were detected in virologic failures. B/F/TAF discontinuations accounted for 10.2% (200). Simplification was the most common reason for discontinuation in 3.8% (74) of patients. Conclusion: In long-term virologically controlled PLWH, B/F/TAF achieved high efficacy rates and slightly improved immune status in women and individuals aged 60 and over after 48 and 96 of switching.
MeSH term(s)	Male ; Humans ; Female ; Middle Aged ; Aged ; HIV Infections/drug therapy ; Emtricitabine/therapeutic use ; Retrospective Studies ; Adenine/therapeutic use ; Treatment Outcome ; Drug Combinations ; Heterocyclic Compounds, 4 or More Rings/therapeutic use ; RNA ; Piperazines ; Tenofovir/analogs & derivatives ; Pyridones ; Alanine ; Amides ; Heterocyclic Compounds, 3-Ring
Chemical Substances	tenofovir alafenamide (EL9943AG5J) ; bictegravir (8GB79LOJ07) ; Emtricitabine (G70B4ETF4S) ; Adenine (JAC85A2161) ; Drug Combinations ; Heterocyclic Compounds, 4 or More Rings ; RNA (63231-63-0) ; Piperazines ; Tenofovir (99YXE507IL) ; Pyridones ; Alanine (OF5P57N2ZX) ; Amides ; Heterocyclic Compounds, 3-Ring
Language	English
Publishing date	2024-01-24
Publishing country	England
Document type	Journal Article
ZDB-ID	191709-2
ISSN	1460-2091 ; 0305-7453
ISSN (online)	1460-2091
ISSN	0305-7453
DOI	10.1093/jac/dkae011
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1197: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 124: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Elevated levels of serum CDCP1 in individuals recovering from severe COVID-19 disease.

Blanco, Jose-Ramon / Cobos-Ceballos, María-Jesús / Navarro, Francisco / Sanjoaquin, Isabel / Armiñanzas, Carlos / Bernal, Enrique / Buzon-Martin, Luis / Viribay, Miguel / Pérez-Martínez, Laura / Espejo-Pérez, Simona / Valencia, Borja / Guzman-Aguilar, Jesus / Ruiz-Cubillan, Juan-Jose / Alcalde, Consuelo / Gutierrez-Herrero, Fernando Gustavo / Olalla, Julian / Andres-Esteban, Eva-Maria / Jurado-Gamez, Bernabe / Ugedo, Javier

Aging

2022 Volume 14, Issue 4, Page(s) 1597–1610

Abstract: Background: COVID-19 survivors report residual lung abnormalities after discharge from the hospital. The aim of this study was to identify biomarkers in serum and induced sputum samples from patients after hospitalization for COVID-19.: Methods: ... ...

Abstract	Background: COVID-19 survivors report residual lung abnormalities after discharge from the hospital. The aim of this study was to identify biomarkers in serum and induced sputum samples from patients after hospitalization for COVID-19. Methods: Patients admitted to hospitals in Spain with laboratory-confirmed COVID-19 were recruited for this study. SARS-CoV-2-infected patients were divided into groups with mild/moderate and severe disease according to the severity of their symptoms during hospitalization. Levels of 92 biomarkers were measured in serum and induced sputum samples. Results: A total of 108 patients (46.2% severe cases) were included in this study. The median number of days after the onset of symptoms was 104. A significant difference was observed in diffusing capacity for carbon monoxide (DLCO), an indicator of lung function, whereby DLCO <80% was significantly lower in severe cases (p <0.001). Differences in inflammatory biomarkers were observed between patients with mild/moderate and severe disease. For some biomarkers, correlations in serum and induced sputum levels were detected. Independent predictors of severe disease were DLCO <80% and the serum CDCP1 value. Conclusions: Higher levels of CDCP1 remain after hospital discharge and are associated with the severity of COVID-19. The possible prognostic implications warrant further investigation.
MeSH term(s)	Antigens, Neoplasm/analysis ; Antigens, Neoplasm/blood ; Biomarkers/blood ; COVID-19/blood ; Cell Adhesion Molecules/analysis ; Cell Adhesion Molecules/blood ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; Severity of Illness Index ; Sputum/chemistry
Chemical Substances	Antigens, Neoplasm ; Biomarkers ; CDCP1 protein, human ; Cell Adhesion Molecules
Language	English
Publishing date	2022-02-16
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	1945-4589
ISSN (online)	1945-4589
DOI	10.18632/aging.203898
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.

Iglesias-Julián, Enrique / López-Veloso, María / de-la-Torre-Ferrera, Noelia / Barraza-Vengoechea, Julio Cesar / Delgado-López, Pedro David / Colazo-Burlato, María / Ubeira-Iglesias, Marta / Montero-Baladía, Miguel / Lorenzo-Martín, Andrés / Minguito-de-la-Iglesia, Javier / García-Muñoz, Juan Pablo / Sanllorente-Sebastián, Rodrigo / Vicente-González, Blanca / Alemán-Alemán, Ana / Buzón-Martín, Luis

Journal of autoimmunity

2020 Volume 115, Page(s) 102537

Abstract: Objective: Severely ill COVID-19 patients may end in acute respiratory distress syndrome (ARDS) and multi-organ failure. Some of them develop a systemic hyperinflammatory state produced by the massive release of inflammatory agents, known as cytokine ... ...

Abstract	Objective: Severely ill COVID-19 patients may end in acute respiratory distress syndrome (ARDS) and multi-organ failure. Some of them develop a systemic hyperinflammatory state produced by the massive release of inflammatory agents, known as cytokine storm syndrome (CSS). Inhibition of IL-1 by Anakinra (ANK) is a potential life-saving therapy for severe CSS cases. We propose a rationale for the use of subcutaneous ANK and review our initial experience in a small cohort of severe COVID-19 CSS patients. Methods: Retrospective cohort study of COVID-19 patients developing ARDS (PaO2/FiO2 <300) and exhibiting signs of hyperinflammation (ferritin >1000 ng/mL and/or d-dimers > 1.5 μg/mL, plus IL-6 < 40 mg/mL) that received ANK. For comparison, a propensity score matched historical cohort of patients treated with IL-6 inhibitor Tocilizumab (TCZ) was used. Patients had previously received combinations of azithromycin, hydroxy-chloroquine, and methyl-prednisolone. Laboratory findings, respiratory function and adverse effects were monitored. Resolution of ARDS within the first 7 days of treatment was considered a favorable outcome. Results: Subcutaneous ANK (100 mg every 6 h) was given to 9 COVID-19 ARDS CSS patients (77.8% males). Median age was 62 years (range, 42 to 87). A TCZ cohort of 18 patients was selected by propensity score matching and treated with intravenous single dose of 600 mg for patients weighing >75 Kg, or 400 mg if < 75 Kg. Prior to treatment, median PaO2/FiO2 ratio of the ANK and TCZ cohorts were 193 and 249, respectively (p = 0.131). After 7 days of treatment, PaO2/FiO2 ratio improved in both groups to 279 (104-335) and 331 (140-476, p = 0.099) respectively. On day 7, there was significant reduction of ferritin (p = 0.046), CRP (p = 0.043), and IL-6 (p = 0.043) levels in the ANK cohort but only of CRP (p = 0.001) in the TCZ group. Favorable outcome was achieved in 55.6% and 88.9% of the ANK and TCZ cohorts, respectively (p = 0.281). Two patients that failed to respond to TCZ improved after ANK treatment. Aminotransferase levels significantly increased between day 1 and day 7 (p = 0.004) in the TCZ group. Mortality was the same in both groups (11%). There were not any opportunistic infection in the groups nor other adverse effects attributable to treatment. Conclusion: Overall, 55.6% of COVID-19 ARDS CSS patients treated with ANK exhibited favorable outcome, not inferior to a TCZ treated matched cohort. ANK may be a potential alternative to TCZ for patients with elevated aminotransferases, and may be useful in non-responders to TCZ.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antirheumatic Agents/therapeutic use ; Cohort Studies ; Cytokine Release Syndrome/drug therapy ; Disease Progression ; Female ; Humans ; Injections, Subcutaneous ; Interleukin 1 Receptor Antagonist Protein/therapeutic use ; Interleukin-1/antagonists & inhibitors ; Interleukin-6/antagonists & inhibitors ; Male ; Middle Aged ; Respiratory Distress Syndrome/drug therapy ; SARS-CoV-2/physiology ; Spain ; COVID-19 Drug Treatment
Chemical Substances	Antibodies, Monoclonal, Humanized ; Antirheumatic Agents ; Interleukin 1 Receptor Antagonist Protein ; Interleukin-1 ; Interleukin-6 ; tocilizumab (I031V2H011)
Keywords	covid19
Language	English
Publishing date	2020-08-20
Publishing country	England
Document type	Journal Article
ZDB-ID	639452-8
ISSN	1095-9157 ; 0896-8411
ISSN (online)	1095-9157
ISSN	0896-8411
DOI	10.1016/j.jaut.2020.102537
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2368: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito